FY2025 EPS Estimates for PVLA Lowered by Cantor Fitzgerald

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of Palvella Therapeutics in a report issued on Thursday, November 13th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings of ($3.40) per share for the year, down from their previous estimate of ($2.87). Cantor Fitzgerald has a “Overweight” rating and a $200.00 price target on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. Cantor Fitzgerald also issued estimates for Palvella Therapeutics’ FY2026 earnings at ($3.77) EPS.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Tuesday, November 11th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18).

PVLA has been the subject of a number of other reports. Raymond James Financial set a $54.00 target price on shares of Palvella Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, August 5th. Oppenheimer reaffirmed an “outperform” rating on shares of Palvella Therapeutics in a research note on Tuesday, November 11th. Stifel Nicolaus raised their target price on shares of Palvella Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Lifesci Capital began coverage on Palvella Therapeutics in a report on Monday, August 4th. They set an “outperform” rating and a $90.00 target price on the stock. Finally, Canaccord Genuity Group increased their price target on Palvella Therapeutics from $90.00 to $148.00 and gave the company a “buy” rating in a report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Palvella Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $104.50.

Palvella Therapeutics Stock Performance

NASDAQ PVLA opened at $81.64 on Monday. The business has a fifty day moving average price of $69.33 and a 200 day moving average price of $45.36. Palvella Therapeutics has a one year low of $11.17 and a one year high of $87.01. The company has a market cap of $966.29 million, a P/E ratio of -21.54 and a beta of -0.05.

Hedge Funds Weigh In On Palvella Therapeutics

Hedge funds have recently modified their holdings of the business. Archer Investment Corp purchased a new position in Palvella Therapeutics during the 3rd quarter valued at about $28,000. Russell Investments Group Ltd. acquired a new stake in shares of Palvella Therapeutics during the third quarter worth about $36,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Palvella Therapeutics in the second quarter valued at approximately $37,000. JPMorgan Chase & Co. grew its holdings in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Palvella Therapeutics in the second quarter valued at approximately $85,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.